|
|
| (83 intermediate revisions by 5 users not shown) |
| Line 1: |
Line 1: |
| ==Investigational Therapies==
| | #REDIRECT[[COVID-19#Management_by_Patient_Category]] |
| Treatment for those infected with [[SARS-CoV-2]] focuses on supportive care which includes symptomatic management, hand hygiene and social distancing. While many treatments are under investigation there is no proven efficacy of any drug for human as of April 8th 2020.<ref>Auwaerter. Johns Hopkins Antibiotic guide. Coronavirus COVID-19. April 8 2020</ref>.Medication management at this time is targeted towards those requiring inpatient admission.
| |
| *Symptomatic management
| |
| *[[Antivirals]]
| |
| **[[Lopinavir]]/[[Ritonavir]]
| |
| ***Known in the U.S as Kaletra, this HIV medication has been widely used in China to treat COVID patients.<ref>https://www.reuters.com/article/us-health-coronavirus-china-wuhan-hospit/key-china-coronavirus-hospital-says-hiv-drug-beneficial-to-patients-idUSKCN21R1LX</ref>.
| |
| ***An RCT with 199 confirmed COVID-19 positive patients concluded that there was no benefit to treating hospitalized patients with [[Lopinavir]]/[[Ritonavir]] versus supportive care.<ref>Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., ... & Li, X. (2020). A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine.</ref>
| |
| **[[Remdesivir]]
| |
| ***Previously used to treat Ebola<ref>Auwaerter. Johns Hopkins Antibiotic guide. Coronavirus COVID-19. April 8 2020</ref> this medication inhibits viral RNA polymerase and has shown some promisinng invitro activity against [[SARS-CoV-2]].
| |
| ***A recent small study among 53 patients with severe symptoms from COVID-19 were given [[Remdesivir]] for compassionate use. 68% percent of patients showed some clinical improvement.<ref>Grein, J., Ohmagari, N.,...Oda, R (2020). Compassionate Use of Remdesivir for Patients with Severe COVID-19. New England Journal of Medicine.</ref>
| |
| ***A large NIH funded trial is currently underway to assess the efficacy of this medication <ref>https://clinicaltrials.gov/ct2/show/NCT04280705</ref>
| |
| ***Consider using in hospitalized patients with severe symptoms and significant Oxygen requirements
| |
| ***Contact Gilead directly for use: compassionateaccess@gilead.com
| |
| **[[Oseltamivir]]
| |
| ***Several small trials have not shown any benefit in patients with COVID-19. <ref>Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. E-pub Date: aheadofprint February 2020.
| |
| DOI # 10.1001/jama.2020.1585 . https://www.ncbi.nlm.nih.gov/pubmed/32031570 </ref>
| |
| **[[Baloxavir marboxil]]
| |
| **[[Favipiravir]]
| |
| **[[Ribavirin]]
| |
| *[[Chloroquine]]/[[Hydroxychloroquine]]
| |
| *[[Immunomodulators]]
| |
| *[[IVIG]]
| |
| *Convalescent Plasma
| |
| **Involves using plasma from patients who recovered from COVID-19 which possibly contain antibodies to [[SARS-CoV-2]]
| |
| *[[Vaccine]]
| |
| | |
| ==Contraindicated Therapies==
| |
| | |
| ==See Also==
| |
| {{COVID see also}}
| |
| | |
| ==References==
| |
| | |
| [[Category:COVID-19]]
| |
